239.20
-4.67 (-1.91%)
| Previous Close | 243.87 |
| Open | 243.11 |
| Volume | 19,836 |
| Avg. Volume (3M) | 512,998 |
| Market Cap | 9,263,235,072 |
| Price / Earnings (TTM) | 223.55 |
| Price / Earnings (Forward) | 54.64 |
| Price / Sales | 8.41 |
| Price / Book | 8.22 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 |
| Profit Margin | 3.41% |
| Operating Margin (TTM) | 12.45% |
| Diluted EPS (TTM) | 1.09 |
| Quarterly Revenue Growth (YOY) | 16.30% |
| Quarterly Earnings Growth (YOY) | 256.50% |
| Total Debt/Equity (MRQ) | 18.19% |
| Current Ratio (MRQ) | 6.30 |
| Operating Cash Flow (TTM) | 179.16 M |
| Levered Free Cash Flow (TTM) | 135.83 M |
| Return on Assets (TTM) | 5.82% |
| Return on Equity (TTM) | 3.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Penumbra, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -2.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.90 |
|
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.64% |
| % Held by Institutions | 91.96% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 350.00 (Canaccord Genuity, 46.32%) | Buy |
| Median | 300.00 (25.42%) | |
| Low | 266.00 (Morgan Stanley, 11.20%) | Hold |
| Average | 305.11 (27.55%) | |
| Total | 7 Buy, 2 Hold | |
| Avg. Price @ Call | 254.60 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 02 Sep 2025 | 300.00 (25.42%) | Buy | 269.50 |
| Morgan Stanley | 31 Jul 2025 | 266.00 (11.20%) | Hold | 252.27 |
| Baird | 30 Jul 2025 | 285.00 (19.15%) | Buy | 254.21 |
| Canaccord Genuity | 30 Jul 2025 | 350.00 (46.32%) | Buy | 254.21 |
| RBC Capital | 30 Jul 2025 | 325.00 (35.87%) | Buy | 254.21 |
| Truist Securities | 30 Jul 2025 | 310.00 (29.60%) | Buy | 254.21 |
| UBS | 30 Jul 2025 | 335.00 (40.05%) | Buy | 254.21 |
| Wells Fargo | 30 Jul 2025 | 290.00 (21.24%) | Buy | 254.21 |
| Citigroup | 09 Jul 2025 | 285.00 (19.15%) | Hold | 244.39 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Sep 2025 | Announcement | New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile |
| 27 Aug 2025 | Announcement | Penumbra, Inc. Names Shruthi Narayan as Company President |
| 20 Aug 2025 | Announcement | Penumbra, Inc. to Present at Upcoming Investor Conferences |
| 30 Jul 2025 | Announcement | Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference |
| 29 Jul 2025 | Announcement | Penumbra, Inc. Reports Second Quarter 2025 Financial Results |
| 01 Jul 2025 | Announcement | Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |